Reneo Pharmaceuticals Inc (RPHM)
1.73
-0.04
(-2.26%)
USD |
NASDAQ |
Apr 18, 16:00
1.74
+0.01
(+0.58%)
After-Hours: 20:00
Reneo Pharmaceuticals Cash from Operations (TTM): -63.68M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -63.68M |
September 30, 2023 | -59.54M |
June 30, 2023 | -51.57M |
March 31, 2023 | -47.41M |
December 31, 2022 | -47.36M |
September 30, 2022 | -41.77M |
June 30, 2022 | -40.65M |
Date | Value |
---|---|
March 31, 2022 | -38.39M |
December 31, 2021 | -37.98M |
September 30, 2021 | -33.37M |
June 30, 2021 | -29.44M |
March 31, 2021 | -22.68M |
December 31, 2020 | -18.54M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-63.68M
Minimum
Dec 2023
-18.54M
Maximum
Dec 2020
-40.95M
Average
-40.65M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
Mirum Pharmaceuticals Inc | -70.94M |
NovaBay Pharmaceuticals Inc | -4.131M |
Palatin Technologies Inc | -26.54M |
iBio Inc | -18.89M |
Theriva Biologics Inc | -19.00M |